Home › Companies › ZURA

Zura Bio

ZURA Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Dermatology Immunology Protein

Most recent annual filing: 2026-03-19

Pipeline (4 active programs)

tibulizumab

ZB-106

Protein Target: IL-17A, BAFF

Hidradenitis Suppurativa Phase 2 subcutaneous Lilly
Diffuse Cutaneous Systemic Sclerosis Phase 2 subcutaneous Lilly

crebankitug

ZB-168

Protein Target: IL-7Rα

Undisclosed indication Phase 1 Pfizer

torudokimab

ZB-880

Protein Target: IL-33

Atopic Dermatitis Phase 2 subcutaneous Lilly

Biotech Distilled coverage (1)

2026-06-30 Zura Bio Limited (ZURA) - Scientific Deep Dive for Tibulizumab and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.